Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 CIPLA   MYLAN
EQUITY SHARE DATA
    CIPLA
Mar-23
MYLAN
Dec-18
CIPLA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,1853,965-   
Low Rs8522,182-   
Sales per share (Unadj.) Rs281.91,824.3-  
Earnings per share (Unadj.) Rs35.149.5-  
Cash flow per share (Unadj.) Rs49.7391.1-  
Dividends per share (Unadj.) Rs8.500-  
Avg Dividend yield %0.80-  
Book value per share (Unadj.) Rs289.21,973.5-  
Shares outstanding (eoy) m807.15514.50-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x3.61.7 214.5%   
Avg P/E ratio x29.062.0 46.7%  
P/CF ratio (eoy) x20.57.9 261.1%  
Price / Book Value ratio x3.51.6 226.1%  
Dividend payout %24.20-   
Avg Mkt Cap Rs m822,1641,581,265 52.0%   
No. of employees `000NA35.0 0.0%   
Total wages/salary Rs m38,3010-   
Avg. sales/employee Rs Th026,817.0-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0728.2-  
INCOME DATA
Net Sales Rs m227,531938,595 24.2%  
Other income Rs m5,1210-   
Total revenues Rs m232,653938,595 24.8%   
Gross profit Rs m48,079242,874 19.8%  
Depreciation Rs m11,721175,742 6.7%   
Interest Rs m1,09545,143 2.4%   
Profit before tax Rs m40,38421,989 183.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m12,029-3,498 -343.9%   
Profit after tax Rs m28,35525,487 111.3%  
Gross profit margin %21.125.9 81.7%  
Effective tax rate %29.8-15.9 -187.2%   
Net profit margin %12.52.7 458.9%  
BALANCE SHEET DATA
Current assets Rs m168,051524,111 32.1%   
Current liabilities Rs m50,333382,135 13.2%   
Net working cap to sales %51.715.1 342.0%  
Current ratio x3.31.4 243.4%  
Inventory Days Days7384 87.7%  
Debtors Days Days793 7.0%  
Net fixed assets Rs m117,318182,072 64.4%   
Share capital Rs m1,614500 323.0%   
"Free" reserves Rs m231,8450-   
Net worth Rs m233,4601,015,388 23.0%   
Long term debt Rs m01,095,930 0.0%   
Total assets Rs m290,0672,723,666 10.6%  
Interest coverage x37.91.5 2,546.4%   
Debt to equity ratio x01.1 0.0%  
Sales to assets ratio x0.80.3 227.6%   
Return on assets %10.22.6 391.5%  
Return on equity %12.12.5 483.9%  
Return on capital %17.83.2 558.8%  
Exports to sales %22.60-   
Imports to sales %8.90-   
Net fx Rs m44,0800-   
CASH FLOW
From Operations Rs m32,377195,040 16.6%  
From Investments Rs m-23,885-100,814 23.7%  
From Financial Activity Rs m-9,583-90,861 10.5%  
Net Cashflow Rs m-9681,616 -59.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 83.29 Rs / USD

Compare CIPLA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare CIPLA With: EARUM PHARMACEUTICALS  AAREY DRUGS  VALIANT LABORATORIES LTD.  ZYDUS LIFESCIENCES  INDOCO REMEDIES  



Today's Market

Sensex Today Ends 114 Points Higher | Metal Stocks Shine | VI Tanks 9% Sensex Today Ends 114 Points Higher | Metal Stocks Shine | VI Tanks 9%(Closing)

After opening the day on high, Indian share markets continued the momentum as the session progressed and ended the higher.